1. Pilot study of bevacizumab in combination with docetaxel and cyclophosphamide as adjuvant treatment for patients with early stage HER-2 negative breast cancer, including analysis of candidate circulating markers of cardiac toxicity: ICORG 08–10 trial. (July 2019) Authors: Gullo, Giuseppe; Eustace, Alex J.; Canonici, Alexandra; Collins, Denis M.; Kennedy, Michael J.; Grogan, Liam; Breathhnach, Oscar; McCaffrey, John; Keane, Maccon; Martin, Michael J.; Gupta, Rajnish; Leonard, Gregory; O'Connor, Miriam; Calvert, Paula M.; Donnellan, Paul; Walshe, Janice; McDermott, ... Journal: Therapeutic advances in medical oncology Issue: Volume 11(2019) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗